Is Melanotan II FDA-approved? Tanning claims, evidence, and safety signals

01

Melanotan II is not an approved tanning product

Melanotan II is a synthetic melanocortin analogue promoted online under names including Melanotan 2 and MT2. Sellers may describe it as a tanning peptide, nasal tanning spray, injectable research product, appetite product, or sexual-enhancement compound. Those descriptions do not identify an FDA-approved finished drug.

FDA’s approval system is product-specific. A valid approval requires an application covering the exact product, formulation, route, strength, labeling, applicant, and indicated use. A chemical identifier or reference to studies of melanocortin biology is not that application. Neither is a page describing a product as prescription-only in another country.

Do not confuse Melanotan II with bremelanotide or another melanocortin medicine. Related mechanism or naming does not make products interchangeable. Evidence, formulation, labeling, approved use, and manufacturing controls attach to the specific approved drug—not to everything that activates a related receptor.

02

FDA’s compounding concern is broader than one side effect

FDA’s current safety-risk table says compounded drugs containing Melanotan II may pose immunogenicity risk for certain routes because of possible aggregation or peptide-related impurities. The agency also points to published case reports discussing melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome, and priapism.

That wording should be preserved carefully. FDA does not say the case reports establish an event rate or prove causation in every report. It identifies a serious safety signal alongside quality-characterization concerns. The active substance, impurities, aggregation, concentration, route, handling, and final-product sterility can be separate sources of uncertainty.

A provider should not turn absence of a large trial into a safety claim. Lack of systematic human evidence means important questions remain unanswered. It does not mean harms are impossible, and it does not justify borrowing safety information from a different approved melanocortin product.

03

What the human reports can and cannot tell you

A published U.S. case report describes a patient with acute ischemic priapism after self-administering Melanotan II. The report is clinically important because prolonged ischemic priapism is an emergency and the case required operative management after initial measures failed. It does not estimate how often the event occurs among users.

Case reports can reveal unusual or severe events that deserve investigation, especially when a product is used outside controlled trials. They are also limited: the number of users is unknown, exposure can be self-reported, product identity and purity may not be independently confirmed, co-exposures can be incomplete, and there is no comparison group.

Regulatory pages also summarize reports involving neurologic, skin, kidney, and systemic effects. Consumers should not combine those reports into a guaranteed list of outcomes. The responsible conclusion is that serious signals and major product-quality uncertainties exist while the true frequency and causal contribution remain uncertain.

04

Nasal sprays and injections create different questions, not approval

Social posts sometimes frame nasal products as a safer or cosmetic alternative to injections. Route is a scientific variable, not an authorization. A nasal spray still delivers a substance into the body, and its absorption, local effects, formulation, device performance, contamination controls, and systemic exposure require evidence for that exact product.

Injection adds particular concerns because it bypasses protective barriers and requires appropriate sterility, concentration, container, storage, and administration controls. A lyophilized vial may also require reconstitution, introducing additional opportunities for concentration mistakes or contamination. This guide does not provide mixing, dosing, or administration instructions.

Packaging claims such as laboratory-tested, pharmaceutical grade, research grade, sterile, or high purity need product-specific evidence. A certificate may describe only the tested sample and method; it does not establish clinical safety, lawful marketing, correct labeling, or FDA approval.

05

Recent enforcement shows the market remains active

Australia’s Therapeutic Goods Administration reported in May 2026 that it issued 27 infringement notices over alleged unlawful supply of Melanotan II. TGA said no Melanotan II products were on Australia’s therapeutic-goods register and none were approved there for supply. The action is governed by Australian law and should not be represented as a U.S. FDA action.

The event is relevant context because it shows that unapproved tanning products remain commercially active through online and social channels. TGA separately warns that products sold as sprays, injections, or ingestible tanning agents may be of unknown quality and that a manufactured-looking label does not establish what is inside.

Jurisdictions classify and regulate products differently, so overseas status does not answer U.S. legality. Use the regulator for the relevant country, and use FDA records for U.S. approval and compounding questions.

06

How to verify a Melanotan II offer

Capture the exact product name, ingredient, salt form if stated, route, concentration, seller, manufacturer, claimed use, lot, and label. Ask the seller for the application number behind any FDA-approved claim. Search the exact finished product in Drugs@FDA rather than accepting a substance identifier or NDC as approval.

If a clinic is involved, identify the prescribing clinician and dispensing pharmacy separately and verify each license through the relevant state. Ask whether the product is approved, compounded, investigational, or otherwise unapproved. A provider should explain the source of that classification without implying that 503A or 503B status guarantees quality.

Do not use online reviews, tanning photos, or before-and-after images as safety or efficacy evidence. Anyone with a suspected serious reaction should seek appropriate medical care. Treatment decisions and symptom evaluation require a licensed clinician; FDA MedWatch can receive U.S. adverse-event and product-quality reports.

• →Exact ingredient and route
• →Finished-product approval record
• →Seller, prescriber, and pharmacy identity
• →Lot, label, and storage information
• →Source date and jurisdiction